Condition
Tardive Dyskinesia clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Tardive Dyskinesia clinical trials that are recruiting, at sites in 2 countries (most in United States (4), China (1)). By phase: Phase 4 (3), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 2Countries
Newest Tardive Dyskinesia clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| NBI-1065890 versus placebo for adults with tardive dyskinesia | Phase 2 | Bryant, Arkansas and 17 other locations | Recruiting | Jan 26, 2026 |
| Precise-target rTMS to relieve motor symptoms of tardive dyskinesia | — | Beijing | Recruiting | Sep 15, 2025 |
| Valbenazine for adults with tardive dyskinesia who remain symptomatic on or after a VMAT2 inhibitor | Phase 4 | Bryant, Arkansas and 18 other locations | Recruiting | Aug 5, 2025 |
| Deutetrabenazine for Tardive Dyskinesia in IDD | Phase 4 | Cleveland, Ohio | Recruiting | May 30, 2025 |
| Smoking cessation treatment for schizophrenia patients using varenicline | Phase 4 | Philadelphia, Pennsylvania | Recruiting | Apr 11, 2018 |
All recruiting trials (5)
-
NBI-1065890 versus placebo for adults with tardive dyskinesia
This trial will test if NBI-1065890 reduces involuntary movements in adults with tardive dyskinesia compared with a placebo.
-
Precise-target rTMS to relieve motor symptoms of tardive dyskinesia
This trial will try targeted repetitive transcranial magnetic stimulation (rTMS) to reduce involuntary movements in adults with tardive dyskinesia.
-
Valbenazine for adults with tardive dyskinesia who remain symptomatic on or after a VMAT2 inhibitor
This trial will test whether valbenazine reduces involuntary movements in adults with tardive dyskinesia who still have symptoms while taking or after stopping a VMAT2 inhibitor.
-
Deutetrabenazine for Tardive Dyskinesia in IDD
This study tests whether deutetrabenazine helps reduce tardive dyskinesia in people with intellectual and developmental disabilities who have not previously received this treatment.
-
Smoking cessation treatment for schizophrenia patients using varenicline
This study is testing if the smoking cessation drug varenicline can help people with schizophrenia quit smoking while also managing their movement side effects from antipsychotic medications.
Related topics
Quick answers
How many Tardive Dyskinesia clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (4 trials), China (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 4: 3, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.